MEDI-0618 is under clinical development by AstraZeneca and currently in Phase I for Migraine. According to GlobalData, Phase I drugs for Migraine have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MEDI-0618’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MEDI-0618 is under development for the treatment of migraine. It is administered through intravenous and subcutaneous route. The therapeutic candidate comprises of human immunoglobulin antibody. It acts by targeting PAR2. The therapeutic candidate is a new molecular entity (NME).
It was also under development for the treatment of painful osteoarthritis of knee.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of MEDI-0618’s drug-specific PTSR and LoA scores, buy the report here.